PRESS RELEASES
You may choose to receive automated email notifications when Humanigen publishes new press releases.
Click here to sign up for Humanigen PR alerts.

Published September 23, 2020

Humanigen Announces Thermo Fisher Partnership to Expand Manufacturing for COVID-19 Therapeutic Candidate Lenzilumab

Published September 22, 2020

Humanigen to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

Published September 22, 2020

Humanigen Announces Closing of Public Offering of Common Stock

Published September 17, 2020

Humanigen Announces Pricing of Public Offering of Common Stock and Commencement of Trading on Nasdaq Under the Symbol “HGEN”

Published September 15, 2020

Humanigen Announces Proposed Public Offering of Common Stock and Subsequent Listing on Nasdaq

Published September 15, 2020

Humanigen and Lonza Announce Collaboration to Expand Manufacturing of Humanigen's COVID-19 Therapeutic Candidate Lenzilumab

Published September 14, 2020

Humanigen Announces Review of Lenzilumab Phase 3 Study in COVID-19 by Data Safety Monitoring Board

Published September 4, 2020

Humanigen Announces One-for-Five Reverse Stock Split

Published September 2, 2020

Humanigen to Present at Upcoming Investor Conferences

Published September 1, 2020

Humanigen to Host Investor KOL Conference Call

  • Twitter

©2020 Humanigen, Inc.  All rights reserved